Rosacea News and Research RSS Feed - Rosacea News and Research

Rosacea is a common and chronic skin condition characterized by flushing, burning and stinging of the skin. The symptoms mainly appear on the face, often affecting the nose, cheeks and chin. Whilst it is not known exactly what causes rosacea, certain triggers have been identified. Common risk factors include sunlight exposure and hot weather, stress, certain foods and drinks, strenuous exercise and some medications.

Rosacea is estimated to affect up to 10% of people, with those aged between 30 and 50 being the most commonly affected. Whilst women tend to develop the condition more frequently than men, the symptoms of rosacea often present more severely in men.

Treatments for rosacea focus on managing the symptoms, as there is currently no cure for the condition. Identifying triggers and learning to avoid them play a large role in easing symptoms. Certain medicines, both topical and oral, may also be used to help control flare ups.
Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study. [More]
Study: Nervous system and stress affect inflammatory skin conditions

Study: Nervous system and stress affect inflammatory skin conditions

Anyone who's had a pimple form right before an important event may wonder if stress caused the break out. [More]
Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). [More]
Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives. [More]
Celsus’ expert highlights serious side effects of topical corticosteroids

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care. [More]
Quest Products launches ProVent Rosacea Moisturizing Crème

Quest Products launches ProVent Rosacea Moisturizing Crème

Quest Products, Inc. announces the national launch of ProVent® Rosacea Moisturizing Creme®, a creme formulated to help reduce the appearance of skin conditions often associated with Rosacea, and other skin conditions, including skin redness, age spots, facial rashes, dry skin, and sun-related damage. [More]
Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service. [More]
Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Rural residents who commonly seek treatment for advanced stages of colorectal cancer have been thought to lack access to cancer screening and adjuvant therapy. ... Several theories have been postulated to explain these findings, some of which include low socioeconomic status, lower educational attainment, lack of insurance coverage, underinsurance, and travel distance to health care facilities. [More]

Free medication samples in dermatology offices appear to change prescribing practices for acne

The availability of free medication samples in dermatology offices appears to change prescribing practices for acne, a common condition for which free samples are often available. [More]
Nestlé focuses on meeting world's increasing skin health needs

Nestlé focuses on meeting world's increasing skin health needs

Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world's increasing skin health needs with a scientifically-proven broad range of innovative products. [More]
ZO Skin Health launches new physician retail website

ZO Skin Health launches new physician retail website

ZO Skin Health, Inc., purveyor of innovative skincare solutions and brainchild of renowned dermatologist Zein Obagi, MD, is proud to announce the launch of its new physician retail website. [More]
FDA, USDA approve SALMONELEX as GRAS food processing aid against Salmonella

FDA, USDA approve SALMONELEX as GRAS food processing aid against Salmonella

FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014. [More]
Joint initiative aims to eradicate health disparities among communities of color in the U.S.

Joint initiative aims to eradicate health disparities among communities of color in the U.S.

The world's first and largest group medical practice and one of the nation's premier volunteer service organizations of professional African American women are joining forces to eradicate health disparities among communities of color in the United States. Mayo Clinic and The Links, Incorporated have established a formal collaboration that aims to develop a more diverse health care workforce. [More]
Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Signum Dermalogix, Inc. announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the company a Small Business Innovation Research Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis. [More]

IUSL awarded patent for method for changing perception of skin tone

​How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations. [More]
FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013. [More]
Lupin gets tentative approval from FDA for Armodafinil Tablets, Doxycycline Capsules

Lupin gets tentative approval from FDA for Armodafinil Tablets, Doxycycline Capsules

elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration. [More]
Experts and patients share tips on preventing skin cancer

Experts and patients share tips on preventing skin cancer

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. [More]
Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A., today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. [More]
UCLA/Pitt scientists uncover P. acnes virus with potential to kill zits

UCLA/Pitt scientists uncover P. acnes virus with potential to kill zits

Watch out, acne. Doctors soon may have a new weapon against zits: a harmless virus living on our skin that naturally seeks out and kills the bacteria that cause pimples. [More]